top of page

RBC Global Healthcare Conference: With clinical validation that has been seen on the target from a large pharma, Contineum has moved its LPA1R antagonist aggressively into the clinic for IPF

  • May 19
  • 1 min read

CEO Carmine Stengone describes the target, and why he believes Contineum has a best-in-class asset. Plus, background on a key upcoming readout for the company's M1R antagonist that partner JNJ will have in major depressive disorder later this year.





Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page